Quabodepistat (OPC-167832) is a potent antimycobacterial agent, specifically a DprE1 inhibitor, under investigation for the treatment of tuberculosis. This innovative compound acts by disrupting the cell… Read more
Quabodepistat (OPC-167832) is a potent antimycobacterial agent, specifically a DprE1 inhibitor, under investigation for the treatment of tuberculosis. This innovative compound acts by disrupting the cell wall synthesis of Mycobacterium tuberculosis. In pharmaceutical research and development, high-quality reference standards of Quabodepistat, including its racemic mixtures, single enantiomers, and stable isotope labelled compounds like Quabodepistat-d4, are essential for rigorous analytical testing. These analytical markers enable precise impurity profiling and the validation of quantification methods in complex matrices. Laboratories rely on these related compounds to facilitate accurate quality control and to support pharmacokinetic, bioequivalence, and safety studies throughout the drug development lifecycle. By utilizing these specific reference materials, researchers can effectively monitor degradation products and verify the stability of the active ingredient, ensuring compliance with regulatory standards for pharmaceutical purity and consistency.